piracetam has been researched along with Brain Injuries in 49 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Brain Injuries: Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury." | 9.16 | Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinsky, S; Tsuchida, T; van den Anker, J, 2012) |
| "To evaluate the safety and tolerability of treatment with levetiracetam and determine the trough levels of levetiracetam in patients with traumatic brain injury (TBI) who are at high risk for posttraumatic epilepsy (PTE)." | 9.16 | Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinski, S; Tsuchida, T; van den Anker, J, 2012) |
| "To evaluate the prevalence of early seizures after levetiracetam prophylaxis in children with moderate to severe traumatic brain injury." | 7.83 | Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis. ( Chung, MG; O'Brien, NF, 2016) |
| " This study investigates a potential additive neuroprotective effect of levetiracetam combined with hypothermia after hypoxia-induced brain injury in neonatal mice." | 7.83 | Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain. ( Bendix, I; Bertsche, A; Fandrey, J; Felderhoff-Mueser, U; Hoeber, D; Kluever, V; Lueckemann, L; Strasser, K; Thavaneetharajah, S, 2016) |
| "This study describes a case of isolated neutropenia associated with levetiracetam in a 52-year-old man with traumatic brain injury." | 7.81 | Levetiracetam-induced neutropenia following traumatic brain injury. ( Bunnell, K; Pucci, F, 2015) |
| "Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury." | 5.16 | Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinsky, S; Tsuchida, T; van den Anker, J, 2012) |
| "To evaluate the safety and tolerability of treatment with levetiracetam and determine the trough levels of levetiracetam in patients with traumatic brain injury (TBI) who are at high risk for posttraumatic epilepsy (PTE)." | 5.16 | Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy. ( Atabaki, SM; He, J; Herr, D; Klein, P; Levine, Z; McCarter, R; Natale, J; Nogay, C; Pearl, PL; Sandoval, F; Soldin, SJ; Trzcinski, S; Tsuchida, T; van den Anker, J, 2012) |
| "In this prospective, single-center, randomized, single-blinded comparative trial of LEV versus PHT (2:1 ratio) in patients with severe traumatic brain injury (sTBI) or subarachnoid hemorrhage (NCT00618436) patients received IV load with either LEV or fosphenytoin followed by standard IV doses of LEV or PHT." | 5.14 | Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. ( Lindsell, CJ; Sangha, KS; Shutter, LA; Szaflarski, JP, 2010) |
| "We propose that a combination of levetiracetam and amantadine may provide neuroprotective and neurorestorative properties when administered during a period of hyperpyrexia accompanied by any form of mental status changes, particularly if there is a decline in Glasgow Coma Score." | 3.85 | Preserving brain function in a comatose patient with septic hyperpyrexia (41.6 °C): a case report. ( Akinyemi, A; Michel, G; Sanchez-Gonzalez, MA; Sterkel, S, 2017) |
| "To evaluate the prevalence of early seizures after levetiracetam prophylaxis in children with moderate to severe traumatic brain injury." | 3.83 | Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis. ( Chung, MG; O'Brien, NF, 2016) |
| " This study investigates a potential additive neuroprotective effect of levetiracetam combined with hypothermia after hypoxia-induced brain injury in neonatal mice." | 3.83 | Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain. ( Bendix, I; Bertsche, A; Fandrey, J; Felderhoff-Mueser, U; Hoeber, D; Kluever, V; Lueckemann, L; Strasser, K; Thavaneetharajah, S, 2016) |
| "This study describes a case of isolated neutropenia associated with levetiracetam in a 52-year-old man with traumatic brain injury." | 3.81 | Levetiracetam-induced neutropenia following traumatic brain injury. ( Bunnell, K; Pucci, F, 2015) |
| " Secondary end points were presence of early seizures (0 to 7 days post-TBI) or late seizures (8 days post-TBI to phone interview), use of anticonvulsant medication when interviewed, medication-related hospital complications, and a summary of phenytoin (PHT) and LEV dosing regimens." | 3.80 | Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury. ( Gabriel, WM; Rowe, AS, 2014) |
| "Recent data indicate comparable efficacy and safety for levetiracetam (LEV) when compared with phenytoin (PHT) for prophylaxis of early seizures after traumatic brain injury." | 3.78 | A cost-minimization analysis of phenytoin versus levetiracetam for early seizure pharmacoprophylaxis after traumatic brain injury. ( Barnett, CC; Beauchamp, K; Bensard, DD; Biffl, WL; Burlew, CC; Johnson, JL; Moore, EE; Pieracci, FM; Stoval, RT; Tebockhorst, S, 2012) |
| "Both levetiracetam (LEV) and phenytoin (PHT) were associated with a low risk of early postoperative seizures and a moderate risk of later epilepsy." | 3.74 | Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery. ( Bromfield, EB; Hurwitz, S; Milligan, TA, 2008) |
| "A study of 246 patients (with schizophrenia, manic depressive psychoses and psychoorganic syndrome) treated by some drugs of a metabolic action (encephalotropic", "nootropic" drugs, piracetam, piriditol and pantogam) permitted one to determine the place of these preparations in a comprehensive treatment of mental disorders." | 3.66 | [Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders]. ( Avrutskiĭ, GIa; Laskova, NB, 1979) |
| "There was no difference in seizure rate (1." | 2.78 | A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. ( Branco, BC; Demetriades, D; Dubose, J; Gooch, J; Herrold, J; Inaba, K; Menaker, J; Okoye, OT; Scalea, TM, 2013) |
| "Levetiracetam was safe and well tolerated in this population." | 2.78 | Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy. ( Atabaki, SM; He, J; Klein, P; McCarter, R; McGavin, CL; Pearl, PL; Sandoval, F; Trzcinski, S; Tsuchida, T; van den Anker, J; Yu, Y, 2013) |
| "To characterize the steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients requiring seizure prophylaxis after a neurologic injury and to determine which dosing regimens achieve serum concentrations within the recommended therapeutic range of 6-20 μg/ml." | 2.76 | Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. ( Fleck, JD; Jacobi, J; Juenke, JM; Kays, MB; Spencer, DD, 2011) |
| "In patients with encephalopathies, chronic fatigue syndrome was directly associated with the severity of depression." | 2.73 | Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage. ( Batysheva, TT; Boiko, AN; Gusev, EI; Manevich, TM; Matvievskaya, OV, 2007) |
| "Piracetam (Nootropil) is a cytoprotective to brain tissue and improving cerebral blood flow medicine." | 2.69 | [Clinical observations concerning piracetam treatment of patients after craniocerebral injury]. ( Cichoński, J; Gościński, I; Krupa, M; Moskała, M; Polak, J; Sliwonik, S; Sondej, T, 1999) |
| "Similarly, 2 trials reporting seizure incidence at 6 months also had insignificant pooled results while comparing drug efficacy." | 2.48 | Phenytoin versus Leviteracetam for seizure prophylaxis after brain injury - a meta analysis. ( Ghauri, AA; Khan, AA; Shamim, MS; Zafar, SN, 2012) |
| "Antiepileptic prophylaxis reduces early seizures, but their use beyond 1 week does not prevent the development of post-traumatic epilepsy." | 1.43 | Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort. ( Craner, M; Cranley, MR; McGilloway, E, 2016) |
| " These findings may guide (1) future experimental studies assessing minimal effective dosing for neuroprotection and anti-epileptogenesis and (2) treatment guideline updates for seizure prophylaxis post-TBI." | 1.42 | Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI. ( Fowler, L; Hurwitz, M; Wagner, AK; Zou, H, 2015) |
| "Levetiracetam is a new-generation antiepileptic drug that has begun to be used in the treatment of epilepsy." | 1.40 | Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats. ( Balci, S; Beydagi, H; Celik, Y; Erdogan, S; Komur, M; Okuyaz, C; Polat, A; Resitoglu, B; Tamer, L, 2014) |
| "Two patients experienced posttraumatic seizure, 1 in each group." | 1.39 | Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam. ( Goodwin, H; Harris, LH; Haut, ER; Kornbluth, J; Kruer, RM; Slater, LA; Thomas, KP, 2013) |
| " Clinicians should be mindful that standard dosing of these agents may not achieve typical target concentrations in this clinical scenario." | 1.39 | Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient. ( Arora, S; Cook, AM; Davis, J; Pittman, T, 2013) |
| "fosphenytoin (fos-PHT) seizure prevention trial (NCT00618436)." | 1.38 | Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention. ( Lindsell, CJ; Shutter, LA; Steinbaugh, LA; Szaflarski, JP, 2012) |
| "Patients who develop early seizures: 40% good outcome, 50% poor outcome, and 10% death." | 1.37 | Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis. ( Cotton, BA; Holcomb, JB; Kao, LS; Kozar, R, 2011) |
| "Piracetam was found to have positive therapeutic effects on impairments to higher mental (memory, attention, executive) and motor (coordination) functions and on measures of the speeds of cognitive and motor operations." | 1.35 | Sequelae of closed craniocerebral trauma and the efficacy of piracetam in its treatment in adolescents. ( Guzilova, LS; Zavadenko, NN, 2009) |
| " Adolescents from the main group (20 patients) received piracetam in dosage of 40-50 mg/kg (or 1600-2400 mg daily) during one month." | 1.35 | [The consequences of closed traumatic brain injury and piracetam efficacy in their treatment in adolescents]. ( Guzilova, LS; Zavadenko, NN, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (10.20) | 18.7374 |
| 1990's | 4 (8.16) | 18.2507 |
| 2000's | 10 (20.41) | 29.6817 |
| 2010's | 30 (61.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaari, A | 1 |
| Mohamed, AS | 1 |
| Abdelhakim, K | 1 |
| Kauts, V | 1 |
| Casey, WF | 1 |
| Inaba, K | 1 |
| Menaker, J | 1 |
| Branco, BC | 1 |
| Gooch, J | 1 |
| Okoye, OT | 1 |
| Herrold, J | 1 |
| Scalea, TM | 1 |
| Dubose, J | 1 |
| Demetriades, D | 1 |
| Kruer, RM | 1 |
| Harris, LH | 1 |
| Goodwin, H | 1 |
| Kornbluth, J | 1 |
| Thomas, KP | 1 |
| Slater, LA | 1 |
| Haut, ER | 1 |
| DeDea, L | 1 |
| Pearl, PL | 3 |
| McCarter, R | 3 |
| McGavin, CL | 1 |
| Yu, Y | 1 |
| Sandoval, F | 3 |
| Trzcinski, S | 2 |
| Atabaki, SM | 3 |
| Tsuchida, T | 3 |
| van den Anker, J | 3 |
| He, J | 3 |
| Klein, P | 3 |
| Cook, AM | 1 |
| Arora, S | 1 |
| Davis, J | 1 |
| Pittman, T | 1 |
| Komur, M | 2 |
| Okuyaz, C | 2 |
| Celik, Y | 2 |
| Resitoglu, B | 2 |
| Polat, A | 2 |
| Balci, S | 1 |
| Tamer, L | 1 |
| Erdogan, S | 2 |
| Beydagi, H | 2 |
| Bunnell, K | 1 |
| Pucci, F | 1 |
| Gabriel, WM | 1 |
| Rowe, AS | 1 |
| Zou, H | 1 |
| Hurwitz, M | 1 |
| Fowler, L | 1 |
| Wagner, AK | 1 |
| Cranley, MR | 1 |
| Craner, M | 1 |
| McGilloway, E | 1 |
| Chung, MG | 1 |
| O'Brien, NF | 1 |
| Jin, H | 1 |
| Li, W | 1 |
| Dong, C | 1 |
| Ma, L | 1 |
| Wu, J | 1 |
| Zhao, W | 1 |
| Strasser, K | 1 |
| Lueckemann, L | 1 |
| Kluever, V | 1 |
| Thavaneetharajah, S | 1 |
| Hoeber, D | 1 |
| Bendix, I | 1 |
| Fandrey, J | 1 |
| Bertsche, A | 1 |
| Felderhoff-Mueser, U | 1 |
| Giannakaki, V | 1 |
| Triantafyllou, T | 1 |
| Drossos, D | 1 |
| Papapetrou, K | 1 |
| Li, JN | 1 |
| Chen, YM | 1 |
| Arslankoylu, AE | 1 |
| Sterkel, S | 1 |
| Akinyemi, A | 1 |
| Sanchez-Gonzalez, MA | 1 |
| Michel, G | 1 |
| Neznamov, GG | 2 |
| Teleshova, ES | 2 |
| Milligan, TA | 1 |
| Hurwitz, S | 1 |
| Bromfield, EB | 1 |
| Jones, KE | 1 |
| Puccio, AM | 1 |
| Harshman, KJ | 1 |
| Falcione, B | 1 |
| Benedict, N | 1 |
| Jankowitz, BT | 1 |
| Stippler, M | 1 |
| Fischer, M | 1 |
| Sauber-Schatz, EK | 1 |
| Fabio, A | 1 |
| Darby, JM | 1 |
| Okonkwo, DO | 1 |
| Zavadenko, NN | 3 |
| Guzilova, LS | 3 |
| Szaflarski, JP | 2 |
| Sangha, KS | 1 |
| Lindsell, CJ | 2 |
| Shutter, LA | 2 |
| Zaĭtsev, OS | 1 |
| Litvinenko, IV | 1 |
| Emelin, AIu | 1 |
| Vorob'ev, SV | 1 |
| Lobzin, VIu | 1 |
| Iznak, EV | 1 |
| Iznak, AF | 1 |
| Pankratova, EA | 1 |
| Guzilova, IuI | 1 |
| Cotton, BA | 1 |
| Kao, LS | 1 |
| Kozar, R | 1 |
| Holcomb, JB | 1 |
| Spencer, DD | 1 |
| Jacobi, J | 1 |
| Juenke, JM | 1 |
| Fleck, JD | 1 |
| Kays, MB | 1 |
| Pieracci, FM | 1 |
| Moore, EE | 1 |
| Beauchamp, K | 1 |
| Tebockhorst, S | 1 |
| Barnett, CC | 1 |
| Bensard, DD | 1 |
| Burlew, CC | 1 |
| Biffl, WL | 1 |
| Stoval, RT | 1 |
| Johnson, JL | 1 |
| Steinbaugh, LA | 1 |
| Hayashi, T | 1 |
| Inoue, K | 1 |
| Shinoda, J | 1 |
| Zafar, SN | 1 |
| Khan, AA | 1 |
| Ghauri, AA | 1 |
| Shamim, MS | 1 |
| Herr, D | 2 |
| Natale, J | 2 |
| Levine, Z | 2 |
| Nogay, C | 2 |
| Trzcinsky, S | 1 |
| Soldin, SJ | 2 |
| Xerri, C | 1 |
| Zennou-Azogui, Y | 1 |
| Zarubina, IV | 2 |
| Shabanov, PD | 1 |
| Boiko, AN | 1 |
| Batysheva, TT | 1 |
| Matvievskaya, OV | 1 |
| Manevich, TM | 1 |
| Gusev, EI | 1 |
| Promyslov, MS | 1 |
| Demchuk, ML | 1 |
| Molnár, P | 1 |
| Gaál, L | 1 |
| Horváth, C | 1 |
| Gościński, I | 1 |
| Moskała, M | 1 |
| Cichoński, J | 1 |
| Polak, J | 1 |
| Krupa, M | 1 |
| Sliwonik, S | 1 |
| Sondej, T | 1 |
| Avrutskiĭ, GIa | 1 |
| Laskova, NB | 1 |
| Godard, JP | 1 |
| Goerens, C | 1 |
| Grelier, C | 1 |
| Lekomtsev, VT | 1 |
| Sharova, EV | 1 |
| Potapov, AA | 1 |
| Kulikov, MA | 1 |
| Strnad, P | 2 |
| Misurec, J | 1 |
| Strnadová, V | 1 |
| Bystrický, Z | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Levetiracetam Treatment of Neonatal Seizures: A Multi-Centre Randomized Blinded Controlled Study of the Efficacy of Oral Levetiracetam as First Line Treatment for Neonatal Seizures in China[NCT02550028] | Phase 1/Phase 2 | 60 participants (Actual) | Interventional | 2015-09-01 | Terminated (stopped due to The study was concluded as planned upon reaching its predetermined endpoint, which included the completion of data collection and achievement of the necessary sample size for statistical significance.) | ||
| A Pharmacokinetic Analysis of Levetiracetam Prophylaxis in Critically Ill Patients With Severe Traumatic Brain Injury[NCT04836481] | 20 participants (Anticipated) | Observational | 2021-01-01 | Recruiting | |||
| Pilot: Levetiracetam to Prevent Post-Traumatic Epilepsy[NCT01463033] | Phase 2 | 126 participants (Actual) | Interventional | 2005-04-30 | Completed | ||
| Relation Between Renal Resistive Index, Glomerular Hyperfiltration and Hyperdynamic Circulation in Critically Ill Patients With Trauma or Sepsis.[NCT02560402] | 40 participants (Actual) | Observational | 2015-08-31 | Completed | |||
| Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?[NCT03054285] | Phase 4 | 2,300 participants (Anticipated) | Interventional | 2017-07-01 | Recruiting | ||
| Pilot Study of Seizure Prophylaxis With Levetiracetam in Aneurysmal Subarachnoid Hemorrhage[NCT01935908] | Phase 4 | 0 participants (Actual) | Interventional | 2013-05-31 | Withdrawn (stopped due to no funding) | ||
| A Pilot Study of NSICU Assessment of Seizure Prophylaxis With Lacosamide[NCT01110187] | 11 participants (Actual) | Interventional | 2010-05-31 | Terminated (stopped due to Lack of enrollement) | |||
| Assessment of Seizure Prophylaxis Protocols Using Intravenous Levetiracetam in a Neuroscience Intensive Care Unit[NCT00618436] | Phase 4 | 52 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
occurrence of PTE (Post-Traumatic Epilepsy) (NCT01463033)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Levetiracetam | 6 |
| Observational | 8 |
The 66 subjects with acute head injury with a high risk for developing post-traumatic epilepsy that received levetiracetam 55 mg/kg/day in a b.i.d. were monitored for adverse events through the 30 day treatment period. (NCT01463033)
Timeframe: 30 day treatment period
| Intervention | Events (Number) | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Headache | Fatigue | Drowsiness | Memory Impairment | Amnesia | Pain | Irritability | Dizziness | Anorexia | Emotional lability | Insomnia | Cognitive changes | Ataxia | Depression | Hostility | Vertigo | Nausea | Cough | Nervousness | Paraesthesia | Weight gain | Hallucinations | Other | Diplopia | Suicidality | Psychosis | |
| Participants | 28 | 28 | 20 | 9 | 8 | 15 | 10 | 10 | 6 | 7 | 5 | 7 | 6 | 7 | 3 | 1 | 2 | 2 | 5 | 3 | 1 | 5 | 2 | 3 | 3 | 3 |
The primary outcome measure is the incidence of clinical adverse events. These will be followed by daily clinical observations during the hospital stay. Subjects will be evaluated for e.g., seizures, fever, neurological changes, cardiovascular, hematologic and dermatologic abnormalities, liver failure, renal failure, and death; EKGs will be requested as per ICU routines through day 7. (NCT01110187)
Timeframe: baseline to 7 days
| Intervention | number of events experienced (Number) |
|---|---|
| IV LCM | 12 |
| IV fPHT | 21 |
Number of seizures in the first 72 hours based on EEG recording (NCT01110187)
Timeframe: baseline to 72 hours
| Intervention | number of participants with seizures (Number) |
|---|---|
| IV LCM | 0 |
| IV fPHT | 0 |
This was the number of patients in each group who demonstrated seizure activity during the course of the study (NCT00618436)
Timeframe: Duration of study, up to 6 months after the injury
| Intervention | Participants (Number) |
|---|---|
| Levetiracetam | 5 |
| Phenytoin | 3 |
The Disability rating scale (DRS) is frequently used in the rehabilitation literature as a measure of disability. It is a reliable, easily performed test that assesses 8 items (eye opening, verbalization, motor response, feeding, toileting, grooming, level of functioning, employability), and assigns each a numerical score ranging from 0 - 5 based on the category. The domains these 8 items are felt to assess include: alertness, cognition for self-care, dependence, and psychosocial adaptability. The scoring range is from 0-30, with increasing disability levels assigned to higher numerical values. The total DRS is then dichotomized into favorable (disability = none, mild, partial or moderate disability) and unfavorable (disability = moderately severe, severe, extremely severe, vegetative state, extreme vegetative state, death) outcomes. A DRS score of 0-6 was favorable, with any score greater than 6 categorized as unfavorable. (NCT00618436)
Timeframe: Discharge; 3 and 6 months following injury
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| At Discharge | At 3 months | At 6 months | |
| Levetiracetam | 24 | 15 | 17 |
| Phenytoin | 23 | 13 | 9 |
This is an 8 point validated scale that measures disability after brain injury. It is assessed through an in person exam or by phone interview at hospital discharge, 3 months and 6 months after injury. The categories are: 1 = dead; 2 = vegetative state; 3 = severe disability, low level; 4 = severe disability, high level; 5 = moderate disability, low level; 6 = moderate disability, high level; 7 = good recovery - low level; 8 = good recovery - high level. Specific questions and activities are assessed to determine into which category the patient falls. (NCT00618436)
Timeframe: at discharge; 3 and 6 months following injury
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| At Discharge | At 3 months | At 6 months | |
| Levetiracetam | 2 | 3 | 3 |
| Phenytoin | 2 | 3 | 3 |
4 reviews available for piracetam and Brain Injuries
| Article | Year |
|---|---|
Levetiracetam versus phenytoin for seizure prophylaxis in brain injured patients: a systematic review and meta-analysis.
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Phenytoin; Piracetam; Post-Exposure Prophyla | 2017 |
Post-Traumatic Bifrontoparietal Extradural Hematoma with Superior Sagittal Sinus Detachment: A Case Report and Review of the Literature.
Topics: Adult; Anticoagulants; Anticonvulsants; Brain Injuries; Drug Therapy, Combination; Hematoma, Epidura | 2016 |
[Comparisons of efficacy and safety of levetiracetam versus phenytoin for seizure prophylaxis in patients with brain injury: a meta analysis].
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Phenytoin; Piracetam; Randomized Controlled | 2016 |
Phenytoin versus Leviteracetam for seizure prophylaxis after brain injury - a meta analysis.
Topics: Adult; Aged; Brain Injuries; Causality; Comorbidity; Convulsants; Female; Humans; Levetiracetam; Mal | 2012 |
10 trials available for piracetam and Brain Injuries
| Article | Year |
|---|---|
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Dose-Response Relations | 2013 |
Results of phase II levetiracetam trial following acute head injury in children at risk for posttraumatic epilepsy.
Topics: Adolescent; Anticonvulsants; Brain Injuries; Child; Craniocerebral Trauma; Epilepsy, Post-Traumatic; | 2013 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
Prospective, randomized, single-blinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Female; Humans; Infusions, Intravenous; Levetiracetam; Male; | 2010 |
[Clinical features of the formation and possibilities of treatment of posttraumatic cognitive disturbances].
Topics: Brain Injuries; Cognition Disorders; Excitatory Amino Acid Antagonists; Female; Humans; Magnetic Res | 2010 |
[Electrophysiological correlates of efficacy of nootropic drugs in the treatment of consequences of traumatic brain injury in adolescents].
Topics: Adolescent; Amino Acids; Asthenia; Brain Injuries; Child; Electroencephalography; Female; Humans; Ma | 2010 |
Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients.
Topics: Anticonvulsants; Brain Injuries; Critical Care; Female; Hematoma, Subdural; Humans; Infusions, Intra | 2011 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Anticonvulsants; Area | 2012 |
Results of phase 2 safety and feasibility study of treatment with levetiracetam for prevention of posttraumatic epilepsy.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Child; Chr | 2012 |
Characteristics of the formation of chronic fatigue syndrome and approaches to its treatment in young patients with focal brain damage.
Topics: Adult; Brain Injuries; Calcium Channel Blockers; Cinnarizine; Drug Therapy, Combination; Fatigue Syn | 2007 |
[Clinical observations concerning piracetam treatment of patients after craniocerebral injury].
Topics: Brain Injuries; Cerebrovascular Circulation; Glasgow Coma Scale; Humans; Neuroprotective Agents; Pir | 1999 |
35 other studies available for piracetam and Brain Injuries
| Article | Year |
|---|---|
Changing trends in the use of seizure prophylaxis after traumatic brain injury: a shift from phenytoin to levetiracetam.
Topics: Abbreviated Injury Scale; Adult; Anticonvulsants; Brain Injuries; Female; Humans; Levetiracetam; Mal | 2013 |
Phenytoin or levetiracetam for seizure prophylaxis in TBI.
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Phenytoin; Piracetam; Seizures | 2012 |
Augmented renal clearance of vancomycin and levetiracetam in a traumatic brain injury patient.
Topics: Anti-Bacterial Agents; Anticonvulsants; Bacterial Infections; Brain Injuries; Drug Monitoring; Femal | 2013 |
Neuroprotective effect of levetiracetam on hypoxic ischemic brain injury in neonatal rats.
Topics: Animals; Animals, Newborn; Apoptosis; Brain Injuries; Caspase 3; Catalase; Cell Count; Dose-Response | 2014 |
Levetiracetam-induced neutropenia following traumatic brain injury.
Topics: Anticonvulsants; Brain Injuries; Humans; Levetiracetam; Male; Middle Aged; Neutropenia; Piracetam | 2015 |
Long-term comparison of GOS-E scores in patients treated with phenytoin or levetiracetam for posttraumatic seizure prophylaxis after traumatic brain injury.
Topics: Adult; Aged; Anticonvulsants; Brain Injuries; Female; Humans; Levetiracetam; Male; Mental Status Sch | 2014 |
Abbreviated levetiracetam treatment effects on behavioural and histological outcomes after experimental TBI.
Topics: Animals; Brain Injuries; Contusions; Disease Models, Animal; Dose-Response Relationship, Drug; Drug | 2015 |
Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort.
Topics: Adult; Anticonvulsants; Brain Injuries; Carbamazepine; Case-Control Studies; Chemoprevention; Cohort | 2016 |
Prevalence of Early Posttraumatic Seizures in Children With Moderate to Severe Traumatic Brain Injury Despite Levetiracetam Prophylaxis.
Topics: Adolescent; Anticonvulsants; Brain Injuries; Child; Child, Preschool; Female; Humans; Infant; Infant | 2016 |
Effects of Different Doses of Levetiracetam on Aquaporin 4 Expression in Rats with Brain Edema Following Fluid Percussion Injury.
Topics: Animals; Aquaporin 4; Blotting, Western; Brain; Brain Edema; Brain Injuries; Dose-Response Relations | 2016 |
Dose-dependent effects of levetiracetam after hypoxia and hypothermia in the neonatal mouse brain.
Topics: Animals; Animals, Newborn; Anticonvulsants; Anxiety; Apoptosis; Behavior, Animal; Brain; Brain Injur | 2016 |
Is levetiracetam neuroprotective in neonatal rats with hypoxic ischemic brain injury?
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Brain Injuries; Disease Models, Animal; Dose-Response R | 2016 |
Preserving brain function in a comatose patient with septic hyperpyrexia (41.6 °C): a case report.
Topics: Adult; Amantadine; Anticonvulsants; Brain; Brain Injuries; Cognition Disorders; Coma; Dopamine Agent | 2017 |
[A comparative study of noopept and piracetam in the treatment of mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin].
Topics: Adolescent; Adult; Brain Diseases; Brain Injuries; Cognition Disorders; Dipeptides; Humans; Middle A | 2008 |
Efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery.
Topics: Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain; Brain Injuries; Drug Tolerance; Drug-Related | 2008 |
Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury.
Topics: Adult; Brain Injuries; Cohort Studies; Electroencephalography; Epilepsy, Post-Traumatic; Female; Hum | 2008 |
Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin.
Topics: Adolescent; Adult; Brain Diseases; Brain Injuries; Cognition Disorders; Dipeptides; Humans; Middle A | 2009 |
Sequelae of closed craniocerebral trauma and the efficacy of piracetam in its treatment in adolescents.
Topics: Adolescent; Age Factors; Attention; Brain Injuries; Child; Female; Follow-Up Studies; Humans; Male; | 2009 |
[Selection of neuromethabolic drug in severe brain injury].
Topics: Aminoquinolines; Brain Injuries; Cognition Disorders; Humans; Intercellular Signaling Peptides and P | 2010 |
Cost-utility analysis of levetiracetam and phenytoin for posttraumatic seizure prophylaxis.
Topics: Adult; Anticonvulsants; Brain Injuries; Cost-Benefit Analysis; Decision Trees; Female; Glasgow Outco | 2011 |
A cost-minimization analysis of phenytoin versus levetiracetam for early seizure pharmacoprophylaxis after traumatic brain injury.
Topics: Adult; Anticonvulsants; Brain Injuries; Cost Control; Cost-Benefit Analysis; Decision Trees; Drug Co | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
Initial EEG predicts outcomes in a trial of levetiracetam vs. fosphenytoin for seizure prevention.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Brain Injuries; Disability Evaluation; | 2012 |
[Effect of levetiracetam on intractable secondarily generalized seizure and depression].
Topics: Anticonvulsants; Brain Injuries; Depression; Humans; Levetiracetam; Male; Middle Aged; Piracetam; Se | 2012 |
Influence of the postlesion environment and chronic piracetam treatment on the organization of the somatotopic map in the rat primary somatosensory cortex after focal cortical injury.
Topics: Afferent Pathways; Animals; Brain Injuries; Brain Ischemia; Brain Mapping; Cell Death; Cerebral Infa | 2003 |
Drug correction of behavioral reactions and metabolic disorders in rats with craniocerebral trauma.
Topics: Animals; Antioxidants; Benzimidazoles; Body Weight; Brain; Brain Injuries; Carbon Tetrachloride Pois | 2003 |
[Significance of individual resistance to hypoxia for the correction of the brain trauma sequelae].
Topics: Acute Disease; Animals; Benzimidazoles; Brain; Brain Injuries; Disease Susceptibility; Hypoxia; Male | 2003 |
[The consequences of closed traumatic brain injury and piracetam efficacy in their treatment in adolescents].
Topics: Adolescent; Age Factors; Attention; Brain Injuries; Child; Female; Follow-Up Studies; Humans; Male; | 2008 |
Interrelationship between the functional state of the central nervous system and lipid peroxidation level in brain following craniocerebral trauma.
Topics: Amphetamine; Animals; Antioxidants; Behavior, Animal; Brain Chemistry; Brain Injuries; Central Nervo | 1995 |
The impairment of long-term potentiation in rats with medial septal lesion and its restoration by cognition enhancers.
Topics: Animals; Brain Injuries; Cerebellar Nuclei; Ergoloid Mesylates; Long-Term Potentiation; Male; Nootro | 1994 |
[Certain principles for differential utilization of metabolic treatment preparations in the complex therapy of mental disorders].
Topics: Adolescent; Adult; Aged; Bipolar Disorder; Brain Injuries; gamma-Aminobutyric Acid; Humans; Infectio | 1979 |
Usefulness of piracetam in intensive care.
Topics: Alcoholism; Brain Diseases; Brain Injuries; Carbon Monoxide Poisoning; Cerebrovascular Disorders; Ch | 1976 |
[Nootropic agents in the complex treatment of patients with traumatic epilepsy].
Topics: Adult; Brain Injuries; Consciousness Disorders; Drug Therapy, Combination; Epilepsy, Post-Traumatic; | 1990 |
[Effect of piracetam on the functional activity of the brain in patients with craniocerebral injuries].
Topics: Brain; Brain Injuries; Drug Evaluation; Electroencephalography; Epilepsy, Post-Traumatic; Humans; Pi | 1988 |
[The effect of nootropic substances on fluctuations in vigilance tonus in postinjury pseudoneurasthenia. EEG study].
Topics: Adolescent; Adult; Brain Injuries; Electroencephalography; Humans; Middle Aged; Neurasthenia; Pirace | 1985 |
[Severe intracranial injuries and their treatment using piracetam].
Topics: Adolescent; Adult; Aged; Brain Injuries; Electroencephalography; Female; Humans; Male; Middle Aged; | 1985 |